Ad:SMUCKER'S Online Auction
Ads:Current issue FRUIT PROCESSINGWorld Of Fruits 2022Our technical book Apple Juice TechnologyFRUIT PROCESSING Online Special: Instability of fruit-based beveragesFRUIT PROCESSING Online Special: Don’t give clogs a chanceOrange Juice ChainOur German magazine FLÜSSIGES OBST
News 15.12.2016

Tate & Lyle PLC Board Changes

Tate & Lyle PLC announces the appointment of Dr Gerry Murphy as a non-executive director and Chairman-designate of the Company. He will join the Board on 1 January 2017 and will succeed Sir Peter Gershon as Chairman of the Company on 1 April 2017 following Sir Peter’s retirement as a Director on 31 March 2017.

Tate & Lyle PLC announces the appointment of Dr Gerry Murphy as a non-executive director and Chairman-designate of the Company.  He will join the Board on 1 January 2017 and will succeed Sir Peter Gershon as Chairman of the Company on 1 April 2017 following Sir Peter’s retirement as a Director on 31 March 2017.

Dr Murphy is Chairman of The Blackstone Group’s principal European entity. His early career was in the food and drinks sector, primarily with Grand Metropolitan plc (now Diageo plc) and Greencore Group plc, where he was CEO, before becoming CEO of Exel plc, Carlton Communications plc and most recently Kingfisher plc (2003 to 2008). He is a non-executive Director of British American Tobacco plc and Intertrust NV and has held non-executive directorships in a number of London-listed companies including Merlin Entertainments plc from 2013 to 2015.

Upon Dr Murphy’s appointment as a non-executive director, he will join the Corporate Responsibility and Nominations Committees and will assume chairmanship of the Nominations Committee with effect from 1 April 2017.

It is further announced that, having led the Chairman succession process, Liz Airey has informed the Board that she intends to step down as Senior Independent Director on 31 December 2016 and will retire from the Board at the Annual General Meeting in July 2017. Douglas Hurt will assume the role of Senior Independent Director, in addition to his role as Chairman of the Audit Committee, with effect from 1 January 2017.

There are no further disclosures to be made in connection with Dr Murphy’s appointment pursuant to paragraph 9.6.13 of the Financial Conduct Authority’s Listing Rules.

<< Back to overview